May 25, 2017

Intra-Cellular Therapies to Present at the American Society of Clinical Psychopharmacology 2017 Annual Meeting

NEW YORK, May 25, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced it will present four presentations at the American Society of Clinical Psychopharmacology (ASCP) 2017 Annual Meeting being held in Miami, FL, May 29 — June 2, 2017.

At ASCP, the Company will present an overview of the clinical development program for lumateperone, including safety and efficacy data and its potential for rapid antidepressant effects. This presentation is entitled:

"Lumateperone (ITI-007): Late Stage Clinical Program in Schizophrenia" to be presented Tuesday, May 30, 2017 at 5:05 — 5:20 pm ET during the Oral Session — Individual Research Report Session: Advances in Schizophrenia Treatment and Assessment.

The Company will present preclinical and Phase I clinical data supporting the clinical development of ITI-214, its novel phosphodiesterase-1 (PDE1) inhibitor. In these presentations the rationale behind ITI-214's potential for the treatment of CNS indications is described. ITI-214 has anti-inflammatory properties, and as such, may be disease modifying in various neurodegenerative disorders, including Parkinson's and Alzheimer's disease. Data supporting the planned Phase 1/2 clinical trial in patients with Parkinson's disease will also be presented. The presentations are entitled:

"Rationale for the Clinical Development of ITI-214, a PDE1 Inhibitor" to be presented Tuesday, May 30, 2017 at 2:20 — 2:30 pm ET during the Oral Session — Pharmaceutical Pipelines.

"Rationale for the Clinical Development of ITI-214, a PDE1 Inhibitor" to be presented on Thursday, June 1, 2017, 12:30 — 2:00 pm ET during Poster Session II (T47).

The Company will present an overview of ITI-333, a novel modulator of serotonin, dopamine, and mu opiate receptors in preclinical development for the potential treatment of mood disorders including depression, substance use disorders and pain. This presentation is entitled:

"Mechanism of Action of Novel Modulators of Serotonin, Dopamine, and Mu Opiate Receptors for Treatment of Mood Disorders, Substance Use Disorder and Pain" to be presented on Wednesday, May 31, 2017, 11:15 am — 1:00 pm ET during Poster Session I (W32).

About Intra-Cellular Therapies

Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, lumateperone (also known as ITI-007), for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, including Alzheimer's disease, depression and other neuropsychiatric and neurological disorders. Lumateperone, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression and agitation associated with dementia, including Alzheimer's disease. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders.

Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, our clinical and non-clinical development plans; the progress, timing and results of our clinical trials and preclinical studies; our beliefs about the extent to which the results of our clinical trials and preclinical studies to date support new drug application filings for lumateperone; the safety and efficacy of our product development candidates; our beliefs about the potential uses and benefits of our drug product candidates; our development plans for our PDE program, including ITI-214 and development efforts and plans under the caption "About Intra-Cellular

Therapies." All such forward-looking statements are based on management's present expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include but are not limited to the following: our current and planned clinical trials, other studies for lumateperone, and our other product candidates may not be successful or may take longer and be more costly than anticipated; product candidates that appeared promising in earlier research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials; our proposals with respect to the regulatory path for our product candidates may not be acceptable to the FDA; our reliance on collaborative partners and other third parties for development of our product candidates; and the other risk factors detailed in our public filings with the Securities and Exchange Commission. All statements contained in this press release are made only as of the date of this press release, and we do not intend to update this information unless required by law.

Contact:

Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
646-440-9333

Burns McClellan, Inc.
Lisa Burns
Justin Jackson (Media)
jjackson@burnsmc.com
212-213-0006